In patients with UC refractory to medical therapy, is IPAA or permanent ileostomy preferred based on long‑term pouch survival data

for a typical UC patient failing medical therapy, IPAA is the standard restorative option: long-term pouch failure rates run roughly 3–28%, meaning the large majority of pouches survive over the long term, and patients report high satisfaction and quality of life ^1–3. permanent ileostomy remains the alternative when contraindications to IPAA exist (poor sphincter/incontinence, low rectal cancer, anal canal disease) or after pouch failure ². the retrieved evidence does not provide a head-to-head long-term survival comparison that establishes one option as superior for the general UC patient. The choice is driven by patient-specific contraindications and preferences, not by survival data alone. ^2,3

What is known: - Long-term IPAA failure risk is reported between 3% and 28%, varying with the patient population studied. ² - Pelvic sepsis and a diagnosis of Crohn's disease are strongly associated with pouch failure. ² - Most patients report high satisfaction and good quality of life after pouch surgery and would recommend it to others. ³ - Permanent ileostomy or continent ileostomy is indicated when IPAA contraindications exist (incontinence, low rectal cancer, anal canal disease) or after IPAA failure. ²

What is unknown / caveats: - No head-to-head long-term pouch-survival vs permanent-ileostomy comparison in the retrieved excerpts - Wide 3–28% failure range reflects heterogeneous populations, not a single pooled estimate for a 35yo UC patient - The retrieved evidence does not isolate outcomes specific to a 35-year-old or directly compare survival between the two options.

## References

1. Alsafi Z, Snell A, Segal JP. Prevalence of 'pouch failure' of the ileoanal pouch in ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis. 2022;37:357-364. PMID: 34825957.

2. Aytac E, Ashburn J, Dietz DW. Is there still a role for continent ileostomy in the surgical treatment of inflammatory bowel disease?. Inflamm Bowel Dis. 2014;20:2519-25. PMID: 25222659.

3. Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2009;3:395-405. PMID: 19673626.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._